Anteris Technologies Welcomes New Board Members for Growth

Anteris Technologies Welcomes New Board Members for Growth

ANteris Technologies Global Corp., a prominent global player in the structural heart market, recently made significant strides in its leadership. The company is excited to announce the appointments of David Roberts and Gregory Moss to its Board of Directors. This move comes at a crucial time as the company gears up to launch its pivotal DurAVR THV global clinical trial, marking a critical step in its growth strategy.

Strategic Appointments to Enhance Leadership

John Seaberg, Chairman of Anteris Technologies, expressed enthusiasm regarding the new additions to the board. "We are thrilled to welcome David and Gregory to our team," he stated. With their vast experience in the healthcare sector, they will play pivotal roles as the company transitions into this exciting next phase following its recent NASDAQ listing. Furthermore, Seaberg thanked Dr. Wenyi Gu for his valuable contributions and commitment to the company during his tenure.

Profiles of the New Board Members

David Roberts

Mr. David Roberts brings a wealth of experience in the medical device industry. Currently serving as President of LeMaitre Vascular, Inc., he has been with the company since 1997 and has held key positions that shaped its growth trajectory. His tenure at LeMaitre includes significant roles such as Chief Financial Officer and Vice President of Business Development. David has a robust academic background, holding a Bachelor of Arts from Brown University and an MBA from Stanford University. He also serves on the board of multiple medical companies, emphasizing his influence in healthcare.

Gregory Moss

Mr. Gregory Moss is a seasoned legal and business executive, currently the Chief Business and Legal Officer at Evommune, Inc. His prior experience includes a notable role at Kadmon, where he managed legal affairs and compliance, contributing to a major acquisition in the healthcare sector. Gregory’s diverse background in law—as both a solicitor and corporate counsel—equips him with the skills necessary to guide Anteris through its upcoming challenges and opportunities. He is well-educated, with degrees from Macquarie University, and maintains active memberships with several legal associations.

Looking Ahead: The PARADIGM Trial

As David Roberts and Gregory Moss step into their roles, both men will be instrumental in navigating Anteris Technologies through the upcoming global pivotal PARADIGM study, scheduled for the third quarter of 2025. This study aims to secure licensure for the DurAVR THV in the U.S. and the European Medicines Agency (EMA), which will be crucial for bringing innovative heart solutions to patients suffering from aortic stenosis.

About Anteris Technologies

Anteris Technologies Global Corp. is dedicated to the creation and development of innovative medical devices aimed at restoring heart functionality. Founded in Australia, the company has expanded its operations across key markets, including a strong presence in the U.S. Even more importantly, Anteris focuses heavily on research and development, utilizing a team of experts to address various structural heart diseases.

The company's flagship product, the DurAVR THV, represents a significant advancement in treating aortic stenosis. Collaborating with leading cardiac professionals, Anteris designed this transcatheter heart valve, which utilizes patented ADAPT tissue technology. This innovation has already been FDA-approved and demonstrates significant clinical success, providing treatment to over 55,000 patients worldwide.

Connecting with Us

For additional inquiries or deeper engagement regarding Anteris Technologies, potential investors and interested parties can reach out to the company's Investor Relations team. Contact Debbie Ormsby for general inquiries and Malini Chatterjee, Ph.D., for U.S. market-related questions. You can also stay connected with us through our website and social media platforms for the latest updates on our innovations and progress.

Frequently Asked Questions

What is the role of David Roberts at Anteris Technologies?

David Roberts has been appointed to the Board of Directors and brings extensive experience from his role as President of LeMaitre Vascular, Inc.

What is the significance of the PARADIGM Trial?

The PARADIGM Trial is crucial for gaining licensure for the DurAVR THV, facilitating its introduction to the U.S. and EMA markets.

What are Anteris Technologies’ main products?

Anteris Technologies primarily focuses on the DurAVR THV, designed to treat aortic stenosis through advanced tissue technology.

How can I contact Anteris Technologies for investor relations?

You can reach the Investor Relations team at Anteris for inquiries by emailing investor@anteristech.com.

Where can I find more information about Anteris Technologies?

Additional information is available on the company’s website at www.anteristech.com.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.